Allergic rhinitis is one of the most frequent allergic pathologies of the upper respiratory tract. The disease is characterized by chronic inflammation of the allergic mechanism in the nasal mucosa, which causes nasal itching, sneezing, enema and nasal congestion.

To reduce unpleasant symptoms, patients often resort to glucocorticoid nasal spray (containing active ingredients dexamethasone, fluticasone, triamciolon ...), with very strong local anti-inflammatory and antiallergic effects, has been used very widely in the treatment of allergic rhinitis.

However, in addition to the confirmed therapeutic effect, the safety of the drug for the nasal mucosa, especially with prolonged use, is also a matter of great concern. Because topical or prolonged oral glucocorticoids have been shown to cause skin atrophy, prolonged use of glucocorticoid nasal spray worries patients will cause atrophy of the nasal mucosa.

There is no clear evidence that prolonged intranasal spray glucocorticoids can cause mucosal atrophy or other sequelae in the nasal mucosa. Meanwhile, in the control group of patients who did not receive the glucocorticoid spray, the nasal mucosa tended to atrophy, which may be due to the progression of the disease when not treated appropriately caused regression of the nasal mucosa.

With such cases, why not choose for yourself a nasal spray that has a different mechanism of action to limit the consequences of atrophy of the nasal mucosa. Rhinovent is a nasal spray with the active ingredient Ipratopium that has a mechanism of bronchial smooth muscle relaxation, reduces nasal discharge to help reverse the feeling of runny nose, unpleasant nasal allergies without causing atrophy of the nasal mucosa.

See more product information here.